Bioventix (51B) AI Stock Analysis

Bioventix

(Frankfurt:51B)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Exceptional profitabilityExceptionally high and stable margins indicate strong earnings power in Bioventix’s antibody and diagnostic-reagent model. Sustained profitability provides internal funding for operations and shareholder returns, while creating resilience if revenue growth remains modest over the next several quarters.

Negative Factors

Recent revenue slowdownThe shift from positive revenue growth in 2021–2024 to slight contraction in 2025 and modest growth in 2026 signals weaker top-line momentum. If sustained, slower growth could limit operating leverage, reduce expansion opportunities, and place greater reliance on existing margins.

Bioventix (51B) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 104.50M
Dividend Yield: 7.11%
Average Volume (3M): 139
Price to Earnings (P/E): 13.8
Beta (1Y): 0.51
Revenue Growth: -4.35%
EPS Growth: -2.97%
Country: Germany
Employees: 12
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Bioventix Business Overview & Revenue Model

Company Description

Bioventix PLC focuses on the development, manufacturing, and global provision of sheep monoclonal antibodies (SMAs) for various diagnostic purposes. The company's extensive product line features purified SMAs that facilitate testing for critical area...

Bioventix Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:51B against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GB:4BB	52Neutral	GBP 82.07M	-4.57	-316.73%	―	-56.10%	-16.77%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
GB:FAB	49Neutral	GBP 7.51M	-6.06	-97.87%	―	7.38%	44.13%
GB:APTA	43Neutral	GBP 10.23M	-9.83	-46.61%	―	28.35%	57.14%
GB:AVCT	43Neutral	GBP 294.51M	-6.63	-1293.07%	―	―	―
GB:OBD	40Underperform	GBP 14.45M	-0.27	-451.74%	―	33.37%	86.41%

* Healthcare Sector Average

Performance Comparison

DE:51B and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:51B	Bioventix plc	23.20	1.11	5.04%
GB:AVCT	Avacta Group plc	60.50	-11.50	-15.97%
GB:OBD	Oxford BioDynamics	0.11	-0.21	-66.56%
GB:FAB	Fusion Antibodies Plc	6.00	-7.50	-55.56%
GB:4BB	4basebio UK Societas	530.00	-255.00	-32.48%
GB:APTA	Aptamer Group Plc	0.29	-0.51	-63.13%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Bioventix AI Stock Analysis